Cancer drug shows promise in taming rare blood disorder
NCT ID NCT00044304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether the drug imatinib (Gleevec) can safely lower high levels of eosinophils (a type of white blood cell) in people with hypereosinophilic syndrome (HES), a rare condition that can damage organs. About 70 adults and children (age 2 and up) with a specific form of HES or those who didn't respond to steroids will take imatinib daily. The goal is to bring eosinophil counts back to normal and then slowly reduce the drug dose, with close monitoring for side effects and relapse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EOSINOPHILIC MYELOID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New algorithm aims to speed up diagnosis of mysterious high white blood cell counts
- Scientists launch national effort to unravel mysteries of rare blood disorder
- Drug dasatinib tested for rare blood cancers
- New clues to spot a rare blood disorder
- New hope for rare blood disorder: drug targets overactive immune cells
- New drug aims to tame rare blood disorder flares